NDAINTRAVENOUSPOWDER
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VANCOMYCIN HYDROCHLORIDE (vancomycin hydrochloride) by Viatris (2) is clinical pharmacology vancomycin is poorly absorbed after oral administration. First approved in 2018.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Vancomycin hydrochloride is a glycopeptide antibiotic administered intravenously as a powder formulation. It works by inhibiting bacterial cell-wall biosynthesis and altering cell-membrane permeability, with bactericidal activity against gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA). It is a critical agent for serious infections where resistance to beta-lactams is present.
Peak
Peak lifecycle stage with established market presence indicates stable, mature team; limited growth headroom suggests focus on market defense and operational efficiency rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Vancomycin is poorly absorbed after oral administration. In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion…
Worked on VANCOMYCIN HYDROCHLORIDE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.